https://www.selleckchem.com/products/azd9291.html
Checkpoint kinase 1 (CHK1) plays a central role in the response to ****tion stress through modulation of cell-cycle checkpoints and homologous recombination (HR) repair. In BRCA-deficient cancers with or acquired PARP inhibitor resistance, the addition of the CHK1 inhibitor prexasertib to the PARP inhibitor olaparib compromises ****tion fork stability, as well as HR proficiency, allowing for sensitization to PARP inhibition. This study followed a 3+3 design with a 7-day lead-in of olaparib alone, followed by 28-day cycles with pre
Suka
Komentar
Membagikan
